Anika Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, reporting quarterly revenue of $30,594 thousand and a net loss of $311 thousand from continuing operations.

Key Highlights

  • Quarterly revenue: $30,594 thousand for the three months ended September 30, 2026, up from $27,817 thousand in the same period of 2025, according to the filing.
  • Net loss from continuing operations: $311 thousand for Q3 2026, compared to a net loss from continuing operations of $3,175 thousand in Q3 2025.
  • Nine-month revenue: $92,816 thousand for the nine months ended September 30, 2026, versus $82,204 thousand for the same period of 2025.
  • Gross profit: $18,837 thousand for Q3 2026, compared to $15,584 thousand for Q3 2025.
  • Share repurchases: The company repurchased a total of 831 thousand shares of common stock during the nine months ended September 30, 2026, for a combined outflow of $9,542 thousand (consisting of $8,690 thousand and $852 thousand in separate periods, per the equity statements).
  • Cash and cash equivalents: $44,957 thousand at September 30, 2026, down from $57,481 thousand at December 31, 2025.
  • Shares outstanding: 13,395,313 shares of common stock outstanding as of October 30, 2026, per the filing cover page.

Anika Therapeutics Reports Narrowing Losses and Higher Revenue in Third Quarter 2026

Anika Therapeutics, Inc. (NASDAQ:ANIK), a Delaware-incorporated medical technology company headquartered in Bedford, Massachusetts, disclosed its unaudited condensed consolidated financial results for the three and nine months ended September 30, 2026. According to the filing, quarterly revenue reached $30,594 thousand, an increase from $27,817 thousand in the third quarter of 2025. Gross profit for the quarter was reported at $18,837 thousand, compared to $15,584 thousand in the prior-year period. Cost of revenue declined to $11,757 thousand from $12,233 thousand in Q3 2025.

The company reported a loss from operations of $712 thousand for Q3 2026, improved from a loss from operations of $3,233 thousand in Q3 2025. Total operating expenses for the quarter were $19,549 thousand, comprising research and development expenses of $7,895 thousand and selling, general and administrative expenses of $11,654 thousand. Net loss for the quarter was $311 thousand, or $(0.02) per basic and diluted share from continuing operations, according to the filing. For the nine months ended September 30, 2026, the company reported a net loss of $2,058 thousand, compared to a net loss of $11,172 thousand for the same period in 2025.

On the balance sheet, total assets were reported at $189,600 thousand as of September 30, 2026, versus $190,270 thousand at December 31, 2025. Total stockholders' equity stood at $137,577 thousand at the end of the quarter. The filing also reflects stock-based compensation expense of $6,191 thousand in Q1 2026 and additional smaller amounts in subsequent quarters, as well as retirement of common stock for minimum tax withholdings totaling $1,742 thousand across the nine-month period. Inventories increased to $30,351 thousand from $18,787 thousand at year-end 2025, as the filing reports.

What Was Disclosed

Anika Therapeutics filed a 10-Q for the period ended September 30, 2026, reporting improved quarterly revenue of $30,594 thousand, a narrowed net loss of $311 thousand, and total assets of $189,600 thousand, with 13,394 thousand shares outstanding at quarter end.